منبع: Zacks Investment Research
خبرگزاری
سهام
اهمیت متوسط
Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Surpass Estimates
Halozyme Therapeutics (HALO) came out with quarterly earnings of $2.28 per share, beating the Zacks Consensus Estimate of $1.82 per share. This compares to earnings of $1.54 per share a year ago.
نمادهای مرتبط
1
H
HALO
HALO
منبع: Zacks Investment Research
مشاهده منبع